FEBS Letters · 2001 · 150 citations · 15 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologySignal TransductionCancer Cell SignalingCancer ProgressionOncogenic Signaling PathwaysPancreatic CancerPharmacodynamics Of Anticancer DrugsSignal Transduction In CancerAngiotensin Receptor SignalingPancreatic Cancer PharmacotherapyProtein Binding In OncologySelective Binding SitesTherapeutic Growth Inhibition
We investigated the expression of angiotensin II type 1 receptor (AT1) in pancreatic cancer. Both AT1 mRNA and protein were expressed in human pancreatic cancer tissues and cell lines. Binding assays showed that pancreatic cancer cells have specific binding sites for angiotensin II and that binding could be eliminated by treatment with a selective AT1 antagonist in a dose-dependent fashion. Surprisingly, the growth of cancer cells was significantly suppressed by treatment with antagonist, also in a dose-dependent manner. These observations suggest AT1 plays an important role in pancreatic cancer growth. Furthermore, ligand-induced inhibition of AT1 may be a useful therapeutic strategy.
15
Masatoshi Nakajima, Howard G. Hutchinson, Masahiko Fujinaga et al. · Proceedings of the National Academy of Sciences · 1995 · 679 citations
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
Anthony F. Lever, David Hole, C. Gillis et al. · The Lancet · 1998 · 547 citations
Medicine, Oncology, Pharmacology +8